Franklin A Valdera
Overview
Explore the profile of Franklin A Valdera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Decar S, Carpenter E, Adams A, Chick R, Clifton G, Stojadinovic A, et al.
Cancer Treat Res Commun
. 2024 Sep;
41:100843.
PMID: 39305541
Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease...
2.
Carpenter E, Van Decar S, McCarthy P, Valdera F, Adams A, OShea A, et al.
J Surg Oncol
. 2024 May;
130(1):109-116.
PMID: 38801055
Background: The benefit of adjuvant therapy (AT) remains unclear in pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) and surgical resection. Methods: The 2019 National Cancer Database was queried for...
3.
Valdera F, OShea A, Smolinsky T, Carpenter E, Adams A, McCarthy P, et al.
J Surg Oncol
. 2023 Oct;
129(2):244-253.
PMID: 37800378
Introduction: Adjuvant (A) multiagent chemotherapy (MC) is the standard of care for patients with pancreatic adenocarcinoma (PDAC). Tolerating MC following a morbid operation may be difficult, thus neoadjuvant (NA) treatment...
4.
Larson D, Carlsson A, Valdera F, Burgess M, Leatherman L, Shaffer L, et al.
Mil Med
. 2023 Sep;
189(7-8):1505-1513.
PMID: 37776542
Introduction: Immediate evacuation of burn casualties can be challenging in austere environments, and it is predicted to be even more difficult in future multi-domain battlespaces against near-peer foes. Therefore, a...
5.
Carpenter E, Van Decar S, Adams A, OShea A, McCarthy P, Chick R, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37536936
Background: The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor...
6.
Topical Synthetic Platelets Loaded With Gentamicin Decrease Bacteria in Deep Partial-Thickness Burns
Valdera F, Nuutila K, Varon D, Cooper L, Chapa J, Christy S, et al.
J Surg Res
. 2023 Jul;
291:167-175.
PMID: 37422958
Introduction: Prolonged inflammation and infection in burns may cause inadequate healing. Platelet granules contain anti-inflammatory mediators that impact wound healing. Synthetic platelets (SPs) avoid portability and storage difficulties of natural...
7.
McCarthy P, Valdera F, Smolinsky T, Adams A, OShea A, Thomas K, et al.
Front Immunol
. 2023 Mar;
14:1090533.
PMID: 36960052
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer...
8.
Carpenter E, Valdera F, Chauviere M, Krell R
J Surg Res
. 2023 Mar;
287:63-71.
PMID: 36868125
Introduction: Total abdominal colectomy (TAC) with ileostomy is the standard treatment for severe ulcerative colitis (UC). Partial colectomy (PC) with colostomy may present a less morbid treatment option. Methods: The...
9.
Adams A, Carpenter E, Clifton G, Vreeland T, Chick R, OShea A, et al.
Cancer Immunol Immunother
. 2022 Aug;
72(3):697-705.
PMID: 36045304
Background: A randomized, double-blind, placebo-controlled phase 2b trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was conducted in patients with resected stage III/IV melanoma. Dendritic cells (DCs) were...
10.
OShea A, Valdera F, Ensley D, Smolinsky T, Cindass J, Kemp Bohan P, et al.
Clin Immunol
. 2022 Aug;
245:109095.
PMID: 35973640
Rapamycin inhibits the mechanistic (formally mammalian) target of rapamycin (mTOR), an evolutionarily conserved intracellular kinase that influences activation of growth signaling pathways and immune responses to malignancy. Rapamycin has been...